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Dengue virus (DEN) causes the most prevalent arthropod-borne viral illness in humans worldwide. Immune mechanisms that are involved
in protection and pathogenesis of DEN infection have not been fully elucidated due largely to the lack of an adequate animal model.
Therefore, as a first step, we characterized the primary immune response in immunocompetent inbred A/J mice that were infected
intravenously with a non-mouse-adapted DEN type 2 (DEN2) strain. A subset (55%) of infected mice developed paralysis by 14 days post-
infection (p.i.), harbored infectious DEN in the central nervous system (CNS), and had an elevated hematocrit and a decreased white blood
cell (WBC) count. Immunologic studies detected (i) increased numbers of CD69+ splenic natural killer (NK) and B cells at day 3 p.i., (ii)
DEN-specific IgM and IgG responses by days 3 and 7 p.i., respectively, and (iii) splenocyte production of IFNg at day 14 p.i. We conclude
that the early activities of NK cells, B cells and IgM, and later actions of IFNg and IgG likely play a role in the defense against DEN
infection.
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The four dengue virus (DEN) serotypes cause dengue
fever (DF) and dengue hemorrhagic fever/dengue shock
syndrome (DHF/DSS) in humans, with an estimated 100
million new cases of DF and over 250000 cases of DHF/
DSS per year worldwide (Burke and Monath, 2001). DEN
belongs to the Flavivirus genus of the Flaviviridae family of
single-stranded, positive-polarity, enveloped RNA viruses,
which also includes yellow fever (YF) and the Japanese, St.
Louis, and West Nile encephalitis viruses (Burke and
Monath, 2001; Chambers et al., 1990). Primary infection
typically leads to DF, an acute febrile illness that is
characterized by headache, retro-orbital pain, athralgia,
and myalgia, and some DF patients may experience neuro-
logic complications, including vertigo, mental irritability,
and depression (George and Lum, 1997). In comparison,0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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primary infections, may result in the severe, life-threatening
DHF/DSS. Clinically, DHF/DSS manifests as DF with
increased vascular permeability, thrombocytopenia, focal,
or generalized hemorrhages, and in cases of DSS, shock
(Halstead, 1988). In rare instances, DHF/DSS may involve
severe central nervous system (CNS) symptoms, such as
reduced consciousness, convulsions, and encephalitis (Cam
et al., 2001; Ramos et al., 1998; Solomon et al., 2000).
Uncontrolled urbanization and globalization have resulted in
the geographic spread of the DEN-transmitting Aedes
aegypti and Aedes albopictus mosquitoes, co-circulation of
different DEN serotypes, and increased frequency of dengue
epidemics, culminating in the emergence and spread of
DHF/DSS (Gibbons and Vaughn, 2002; Rigau-Perez et al.,
1998). Thus, dengue is now a major public health problem
throughout the world, with no specific treatment or vaccine
currently available.
The immune response to DEN infection is poorly de-
fined, and the immune system may have both protective and
pathogenic roles. In vitro studies suggest that the protective
nature of the immune system involves interferons (IFNs)
Fig. 1. Susceptibility of A/J mice to primary DEN infection. A/J mice were
inoculated via tail-vein with 108 PFU of DEN2, PL046 strain, (DEN group;
n = 51). The control mice (Mock) included mice injected with PBS (n = 10)
or with heat-inactivated 108 PFU of DEN2 (n = 6). Mice were euthanized as
soon as they developed paralysis, as per guidelines of the Office of
Laboratory Animal Care at UC Berkeley. Kaplan–Meier analysis was
performed, and the log rank test yielded P = 0.0002 for mock- versus DEN-
infected mice. The survival curves shown represent combined data from
three separate experiments.
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et al., 1998), antibodies (Abs) (Falgout et al., 1990; Gentry
et al., 1982; Kurane et al., 1986; Russell et al., 1967), and T
cells (Kurane et al., 1989; Mathew et al., 1996). In addition,
in vitro as well as clinical and epidemiological studies
suggest a role for host cross-reactive Abs and DEN sero-
type-cross-reactive Abs and T cells in DEN pathogenesis
(Halstead, 1988; Innis, 1997; Rothman and Ennis, 1999).
However, without an animal model for DEN infection, the
exact mechanisms by which the various immune compo-
nents protect against DEN infection or contribute to DHF/
DSS cannot be clarified. Therefore, to investigate the role of
the immune system in DEN infection in vivo, an adequate
animal model for primary DEN infection is an essential first
step.
The role of the immune system in vivo has not been
examined in the majority of published murine models for
DEN infection because they are created using either
outbred mouse strains whose immune system may vary
from one mouse to another, or mouse brain-adapted DEN
strains with uncertain relevance to human infection. Spe-
cifically, the Swiss albino mouse model (Chaturvedi et al.,
1991) involves outbred mice with variable genetic back-
grounds, although the IFN a, h, and g receptor knock-out
(Johnson and Roehrig, 1999) and BALB/c models (Atra-
sheuskaya et al., 2003; Hotta et al., 1981) use mouse-
adapted DEN. The chimeric severe combined immunode-
ficient (SCID) mice, transplanted with human peripheral
blood mononuclear cells (PBMCs) (Wu et al., 1995),
erythroleukemic K562 cells (Lin et al., 1998), or HepG2
hepatocarcinoma cells (An et al., 1999), are complicated
by variable levels of human cell engraftment and the
altered nature of the murine immune response to both
human cells and DEN. To date, the most suitable murine
model for investigating the role of the immune system in
DEN infection has been the A/J inbred strain that is
inoculated intravenously with a non-mouse-adapted DEN
serotype 2 (DEN2) (Huang et al., 2000).
Since previously published models have not been exten-
sively analyzed at the immunologic level, the current study
was undertaken to characterize the primary immune re-
sponse in A/J mice infected intravenously with a non-
mouse-adapted DEN2 strain. This study describes the im-
munologic elements that are involved in the response of
mice with primary DEN infection. Our results suggest that
the early activities of natural killer (NK) cells, B lympho-
cytes, and IgM and later actions of IFNg and IgG may be
important for clearing primary DEN infection. In addition,
this study extends published results by demonstrating that
the symptomatic mice have (i) increased hematocrit levels,
(ii) decreased white blood cell (WBC) counts, and (iii)
infectious DEN in the spinal cord as well as the brain.
These data provide valuable information for further optimi-
zation of a mouse model for DEN infection and disease. The
immunologic data indicate that the mouse model for prima-
ry DEN infection has considerable potential for dissectingthe interactions between specific elements of the immune
system and DEN.Results
Virologic characteristics
We characterized the A/J mouse model at multiple levels
to define the role of the immune system in protection against
primary DEN infection. A/J mice were intravenously inoc-
ulated with 108 PFU of non-mouse-adapted DEN2 (Taiwa-
nese strain PL046), and a subset (55%) of DEN-infected
mice exhibited paralysis and death within 8–14 days post-
infection (p.i.) (Fig. 1). These results are consistent with a
previously published report using the same DEN strain and
dose, mouse strain, and route of infection (Huang et al.,
2000). The presence of infectious virus in both the brain and
spinal cord from paralytic mice, but not from asymptomatic
mice, was confirmed by indirect plaque assays (data not
shown). The brain and spinal cord samples from all the
paralytic mice harbored DEN2 RNA, as quantitated by real-
time RT-PCR (Fig. 2). Serum, liver, spleen, lymph nodes,
and lung from paralytic mice did not contain detectable
levels of DEN by either plaque assays or real-time RT-PCR.
These results indicate that a significant number of A/J mice
infected with DEN2 develop paralysis and harbor infectious
virus in the central nervous system (CNS).
Hematologic findings
Clinical parameters of DEN infection in humans include
an elevated hematocrit and a decreased WBC count (Green
et al., 1999a; Kalayanarooj et al., 1997; WHO, 1997);
Fig. 2. Level of DEN RNA in the brain and spinal cord of DEN-infected A/J mice. DEN RNAwas isolated from the brain and spinal cord from nine mice with
paralysis and was quantified using real-time RT-PCR. Values are expressed as PFU equivalents of DEN RNA per milligram of total mouse RNA. Results from
individual mice are shown as open triangles (D), while the mean is indicated by a dash (– ). The paralytic mice from two independent experiments are
represented, and the limit of detection of the assay was 1000 PFU equivalents of DEN RNA per milligram of total mouse RNA.
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itored in the infected A/J mice. As compared to the mock-
and DEN-infected mice with no signs of illness at day (d)
14 p.i., the DEN-infected mice with paralysis had a
significantly increased hematocrit (P < 0.001) and a de-
creased WBC count (P < 0.001) (Fig. 3). In contrast, at
both d3 and d7 p.i., all DEN-infected mice presented
hematocrits and WBC counts that were similar to the
mock-infected animals (data not shown). Thus, the ob-
served hematologic abnormalities of symptomatic DEN-
infected mice appear to be consistent with findings in
DEN-infected humans.
Characterization of the immune response
To begin to characterize the primary immune response to
DEN infection in A/J mice, the phenotype of immune cells in
the spleen was assessed by flow cytometric analysis. As a
control for specificity of the immune response, studies were
conducted using mice that were infected with the 17D
vaccine strain of yellow fever (YF), another flavivirus.
Spleen cells were gated according to the forward and side
scatter parameters, and the number of lymphocytes in the
mock- and DEN-infected mice was found approximately
equal at 3, 7, and 14 days p.i. (data not shown). Analyses of
the gated cells for the expression of markers for dendritic
cells (DCs), macrophages, and granulocytes revealed little to
no difference in the number of CD11c+, F4/80+, and Gr1+
cells (data not shown). In contrast, 3 days after infection, the
DEN-infected mice had two times more CD3DX5+NK
cells than the mock-infected mice (P < 0.001) (Fig. 4A),
and more than 50% of these NK cells expressed the early
activation marker CD69, although only 5–10% of NK cellsin the mock-infected animals expressed CD69 (Fig. 4B).
Likewise, at d3 p.i., increased numbers of CD3DX5+NK
cells were present in the spleen of mice infected with live YF,
as compared to that of mice injected with heat-inactivated
YF (Fig. 4A). However, the numbers of CD69+-activated
NK cells in the heat-inactivated YF- and live YF-infected
mice were similar and were significantly lower than in DEN-
infected mice (Fig. 4B). In addition to NK cells, significant
numbers of B and Tcells in the spleen of DEN-infected mice,
but not in the mock-infected controls, expressed CD69 at d3
p.i. (Fig. 5). Ten times more CD19+CD69+B cells (Fig. 5A)
and five times more CD3+CD69+T (both CD4+ and CD8+
subsets) cells were detected in DEN-infected mice than in
mock-infected mice (Fig. 5B), revealing a greater increase in
the number of activated B cells as compared to the number of
activated T cells. The overall percentages of CD69+CD19+,
CD69+CD4+, and CD69+CD8+ lymphocytes in the spleen of
DEN-infected mice were 6.30%, 2.46%, and 1.58%, respec-
tively (Fig. 5C). In comparison, the spleen from mice
infected with live YF did not contain significantly higher
numbers and percentages of CD69+B or T cell subsets than
the spleen from mice that were injected with heat-inactivated
YF (Figs. 5A, B). The percentages of CD69+CD19+,
CD69+CD4+, and CD69+CD8+ splenocytes in YF-infected
mice were 0.74%, 1.26%, and 0.71%, respectively. By d7
p.i., the numbers of NK cells, CD69+NK cells, CD69+B
cells, and CD69+T cells in DEN-infected mice declined to
the levels observed in mock-infected mice (Figs. 4 and 5).
These data indicate that primary DEN infection in mice
results in an early increase in (i) the number and activation of
splenic NK cells and (ii) the number of activated B and T
cells in the spleen. Moreover, this activation of NK, B, and T
cells is observed only in response to DEN, but not to YF
Fig. 3. Elevated hematocrit and reduced WBC count in paralytic A/J mice.
Blood was collected from mice with paralysis between days 8–14 p.i., and
the hematocrit (A) and WBC count (B) were determined manually. Values
were compared to control samples obtained from mock-infected and
asymptomatic DEN-infected mice at d14 p.i., because no difference was
observed in results obtained from the control mice examined on days 8–14
p.i. Data are shown as the averages of results from two different
experiments F SD, with n = 12, n = 11, and n = 15 for the mock, DEN-
asymptomatic, and DEN-paralysis groups, respectively. The mock group of
mice included those injected with PBS (n = 10) or with heat-inactivated
DEN (n = 5). Two-tailed Student’s t Tests were performed to obtain P
values (*). Statistical values for the hematocrits (A): P = 0.39 (mock vs.
DEN-asymptomatic); P < 0.001 (mock vs. DEN-paralysis), P < 0.001
(DEN-asymptomatic vs. DEN-paralysis). Statistical values for the WBC
counts (B): P < 0.05 (mock vs. DEN-asymptomatic); P < 0.001 (mock vs.
DEN-paralysis), P < 0.001 (DEN-asymptomatic vs. DEN-paralysis).
Fig. 4. Early increase in the numbers of CD3DX5+NK cells and
CD3DX5+CD69+-activated NK cells in the spleen of mice with primary
DEN infection. Cells were isolated from mock (E)- and DEN (D)-infected
mouse spleens at d3, d7, and d14 p.i., counted by hemocytometer, and triply
stained with fluorescent Abs against cell surface markers CD3, DX5, and
CD69 for flow cytometric analysis. The percentage of fluorescence-positive
cells out of 50000 gated events was multiplied by the total spleen cell
number, and results were graphed as the average number of lymphocytes
(n = 4–6 mice) F SD. The mock– infected group included mice injected
with PBS alone (n = 2–3 mice) or heat-inactivated DEN (n = 2–3 mice).
Similar results were obtained in two additional experiments. As a control
for specificity, splenocytes were isolated from A/J mice that were
intravenously inoculated with 108 PFU of the YF vaccine strain 17D (o)
(YF group; n = 3 mice) or 108 PFU of heat-inactivated YF (.) (mock
group; n = 3) at d3 p.i. Cells were processed for flow cytometric analysis
exactly as performed for cells from DEN-infected mice. This experiment
was performed twice with similar results.
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NK cell number.
To investigate the biological significance of early NK cell
activation in the spleen, the levels of IFNg and TNFa were
measured in supernatants from unstimulated 24-h splenocyte
cultures by ELISA. A significant amount of IFNg was
present in the spleen culture supernatants from DEN-infected
mice on d14 p.i, but none (limit of detection = 15 pg/ml) was
detected from d3 and d7 p.i. splenocytes (Fig. 6A). IFNgwas
absent in the culture supernatants of spleen cells harvested
from the mock-infected mice at d3, d7, and d14 p.i (Fig. 6A).
To determine the cellular source of IFNg production, CD4+
and CD8+T cells were lysed via treatment of splenocytes
with Ab and complement. Fig. 6B shows decreased levels of
IFNg in splenocytes that were treated either with anti-CD4
and complement, or with both anti-CD4 and anti-CD8 and
complement, indicating that CD4+T cells are the majorproducers of IFNg. In contrast, splenocytes treated with
anti-CD8 and complement did not demonstrate a decrease
in IFNg production. In comparison, TNFa was undetectable
in spleen cell cultures from either mock- or DEN-infected
mice at all three times post-infection (data not shown; limit
of detection = 100 pg/ml). These results indicate that
splenocytes produce IFNg, but not TNFa, in response to
DEN infection later in the course of infection, and that
CD4+T cells, but not CD8+T cells, are the major source of
this IFNg secretion. Since the kinetics of IFNg production by
spleen cells does not appear to correlate with the early
activation of NK cells in the spleen, IFNg production might
not be a major effector function of NK cells during early
DEN infection.
To explore the significance of the early activation of B
cells in the spleen of DEN-infected mice, the Ab response
Fig. 6. IFNg production by splenocytes from DEN-infected mice. Panel A:
Ex vivo splenic leukocytes from mock- or DEN-infected A/J mice at d3, d7,
and d14 p.i. were cultured for 24 h in the absence of stimuli, and IFNg
production in the culture supernatant was quantitated by ELISA. Results
from two experiments were combined and graphed as the average F SD
(n = 4–8 mice). The mock group included mice that received PBS (n = 2
mice) or heat-inactivated DEN (n = 2 mice). The symbol § indicates values
that are below the limit of detection (15 pg/ml). Panel B: CD4+ and CD8+ T
cells were lysed in splenocytes isolated from DEN-infected A/J mice at d14
p.i., as described in Methods, and were then cultured for 24 h in the absence
of stimuli. The level of IFNg in the culture supernatant was measured via
ELISA. This experiment was performed twice (n = 3 mice). Anti-CD4 =
splenocytes treated with anti-CD4 + complement; anti-CD8 = splenocytes
treated with anti-CD8 + complement; both Abs = splenocytes treated with
anti-CD4 + anti-CD8 + complement.
Fig. 5. A larger increase in the number and percentage of CD69+CD19+ B
cells than of CD69+CD3+ T cells in the spleen of DEN-infected mice at d3
p.i. Cells from mock (E)- and DEN (D)-infected mouse spleens at d3, d7,
and d14 p.i. were doubly or triply stained with fluorescent Abs against cell
surface markers CD69, CD19, CD3, CD4, and/or CD8, and analyzed by
flow cytometry. Mock-infected mice were injected with either PBS (n = 2–
3 mice) or heat-inactivated DEN (n = 2–3 mice). A minimum of 50,000
events was gated, and data were plotted as the mean number (panels A and
B) or percentage (panel C) of positive eventsF SD (n = 4–6 mice). Similar
data were reproduced in three independent experiments. In a control
experiment, spleen cells were isolated from A/J mice that were injected with
108 PFU of the YF vaccine strain 17D (o) (YF group; n = 3 mice) or 108
PFU of heat-inactivated YF (.) (mock group; n = 3) at d3 p.i. Cells were
prepared for flow cytometry exactly as described for cells from DEN-
infected mice. This experiment was conducted twice with similar results.
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and uninfected C6/36 cellular antigen were performed to
measure the levels of DEN antigen-specific IgM and IgG.
Similar results were obtained using an ELISA against
purified envelope (E) protein (data not shown). DEN anti-gen-specific IgM was detected in d3, d7, and d14 sera from
both the mock- and DEN-infected mice, after subtracting
binding to uninfected C6/36 cellular antigen (Fig. 7A). IgM
binding to DEN antigen in sera from mock-infected mice at
d3, d7, and d14 p.i was low (mean titer F SD = 1/150 F 1/
100), but higher than negative controls consisting of no
serum or serum from B cell-deficient mice (data not shown).
As compared with the mock-infected mice, the IgM titers in
sera from DEN-infected mice were significantly higher at all
three time-points, and the titers of IgM Abs were greater in
d7 (mean titer F SD = 1/1150 F 1/499) and d14 sera (mean
titerF SD = 1/2250 F 1/1140) than in d3 sera (mean titerF
SD = 1/900 F 1/623), with the highest mean titers in d14
sera. In contrast, DEN-specific IgG Abs were undetectable in
the mock-infected sera and d3 sera from DEN-infected mice
and were present only in d7 and d14 sera from DEN-infected
mice, with the highest titers in d14 sera (Fig. 7B). Together,
these results demonstrate that (i) the mock-infected A/J mice
have natural IgM Abs that react with DEN antigen, (ii) IgM
Fig. 7. Production of DEN antigen-specific Ab titers. Sera from PBS-
injected (Mock) or DEN-infected (DEN) A/J mice were used to measure
DEN antigen-specific Ab titers by ELISA, as described in Methods. Results
from two experiments were combined and plotted as the mean F SD (n =
4–6 mice in the mock group and n = 6–10 mice in the DEN group).
Asterisks (*) in panel A indicate statistically significant differences in the
means between the mock- and DEN-infected mice, as determined by two-
tailed Student’s t tests: P < 0.05, d3 sera; P < 0.001, d7 sera; P < 0.001, d14
sera. In panel B, § symbols represent 1:100 serum dilutions that are below
twice the background level.
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Abs are produced later, between d3 and d7 p.i., and (iii)
levels of both anti-DEN IgM and anti-DEN IgG Abs remain
high at d14 p.i.Discussion
Although various murine models for DEN infection have
been reported, the A/J model is the only immunocompetent
strain with several desirable features for the analysis of the
immune response to DEN infection in vivo. Unlike the
models that have been created using outbred mice, mouse
brain-adapted DEN, or an intracranial route of infection, the
A/J model involves an inbred mouse strain with a uniform
genetic background, a non-mouse brain-adapted DEN strain
that has not acquired mutations during mouse brain passage,
and an intravenous infection route that may be more
physiologically relevant (Huang et al., 2000). In this study,
we used the A/J model to characterize for the first time the
primary immune response to DEN infection in vivo, and
found that DEN infection induced an early increase in thenumber and activation of NK cells, early B and T cell
activation, DEN-specific IgM and IgG production, and late
IFNg production by CD4+T cells.
Virologic characteristics and hematologic findings
A subset of A/J mice in this study developed paralysis
between d8 and d14 p.i., and the brain as well as the spinal
cord contained infectious virus. Similar to published mouse
models for DEN infection, our infected mice exhibited
paralysis within 2 weeks of infection, and tissue surveys
for DEN infection showed that the brain increasingly
accumulated a high viral load as the infection proceeded.
Compared with other models, such as the intraperitoneal
infection of IFN receptor-deficient 129/Sv/Ev mice with a
mouse-adapted DEN (Johnson and Roehrig, 1999), the level
of DEN in the infected A/J brain was lower at d14 p.i. and
was undetectable in the spleen of infected mice at an early
time after infection (data not shown), suggesting that differ-
ences in the viral and mouse strains and route of infection
may control the level of viral replication and site of DEN
tropism. In addition, viral dose was an important parameter
of infection in our model, because paralysis was observed in
mice challenged with 108 PFU, but not with 107 PFU (data
not shown). However, A/J mice inoculated with 108 PFU of
16681, another non-mouse-adapted DEN2 strain, failed to
show clinical symptoms (data not shown), implying a role
for viral determinants in the outcome of infection. Compar-
ison of PL046 with other known DEN2 sequences, together
with mutational analysis, should help identify the virulence
determinants in PL046.
DEN-infected A/J mice with paralysis had an elevated
hematocrit and decreased WBC count, as compared to
mock-infected and asymptomatic DEN-infected mice. De-
hydration may have contributed to increased hematocrit, as
DEN-infected paralytic mice have a compromised ability to
move; however, an increased hematocrit was also observed
in the HepG2-SCID mouse chimera model for DEN infec-
tion (An et al., 1999). This study using A/J mice is the first
mouse model to show decreased WBC counts in response to
disease onset. Further studies, including differential counts,
flow cytometry, platelet counts, and serum albumin level,
are required to understand the significance of this observa-
tion and to extend the relevance of these findings to human
disease. Still, the A/J model may exhibit some key features
of human DEN infection, and it may be used to elucidate the
mechanisms that are responsible for causing hematologic
dysfunctions, including decreased WBC count and elevated
hematocrit.
Characterization of the immune response
Increased number and activation of NK cells
Phenotypic analysis of spleen cells identified the immune
cell types that expressed CD69, a transient cell activation
marker, early in response to DEN infection. Spleen cells
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NK cells and activated NK cells, in the absence of an
increase in the numbers of total splenocytes. These results
support a published observation that peripheral blood mono-
nuclear cell (PBMC) samples obtained from dengue patients
early in the course of illness had significantly more
CD69+NK cells than those from patients with other febrile
illnesses (Green et al., 1999a). Thus, both the mouse and
human findings imply a potential role for activated NK cells
early in DEN infection. In fact, a role for NK cells during
initial DEN infection has previously been implied by studies
demonstrating that human blood NK cells are cytotoxic
against DEN-infected targets (Kurane et al., 1984), and that
infection of human cells with DEN leads to an upregulation
of MHC class I cell surface expression, perhaps as a means
to evade the early NK cell recognition of non-MHC I-
expressing cells (Lobigs et al., 1996). Interestingly, A/J mice
possess lower numbers of NK cells in the blood and spleen
than C57BL/6 mice (Whyte and Miller, 1998), which are
more resistant to infection with both DEN and MCMV
(Brown et al., 2001; Lee et al., 2001). Thus, NK cells may
be important in controlling DEN infection in vivo, as has
been demonstrated for MCMV.
Early B cell activation and IgM production followed by
later IgG production
Three days after infection, DEN-infected mice had a
greater number of activated B cells in the spleen and a
higher level of DEN antigen-specific IgM in sera, as
compared to mock-infected animals. Early activation of B
cells and IgM production have been documented in mice to
be critical for clearing certain viruses, such as rotavirus
(Blutt et al., 2002). Recently, the initial IgM-dependent early
B cell response has been shown to play a key role in limiting
West Nile virus (WNV) infection in mice as well (Diamond
et al., 2003). Further studies are now required to determine
the specificity and neutralizing ability of these anti-DEN
IgM Abs, because humans with primary DEN infection
generate an early DEN-specific IgM response with both a
neutralizing and a cross-reactive nature (Innis, 1997). In
particular, high levels of anti-DEN-NS1 IgM Abs have been
found in patients with both primary and secondary DEN
infections (Huang et al., 1999), and these Abs may cross-
react with endothelial cellular antigens and damage the
endothelial cells (Lin et al., 2003).
Notably, in our study, sera from mock-infected mice
contained a low level of natural, pre-immune IgM Abs that
bind to DEN. Similarly, natural IgMs that recognize certain
influenza virus hemagglutinins have been demonstrated in a
murine model of influenza virus infection (Baumgarth et al.,
1999, 2000). These cross-reactive natural IgM Abs may
provide a first line of defense by accelerating the develop-
ment of the primary immune response, as demonstrated in
experiments using natural serum IgM-deficient mice, whose
major phenotype is a delayed IgG response (Ehrenstein et
al., 1998). However, natural IgM Abs may also have apathogenic role. Specifically, lymphocytic choriomeningitis
virus (LCMV)-induced hypergammaglobulinemia may be
due to the isotype switching from natural IgM Abs (Hun-
ziker et al., 2003). Thus, additional studies are needed to
determine whether the observed natural IgM Abs that bind
to DEN recognize other flaviviruses, as well as the speci-
ficity and neutralizing activity of these Abs.
Characterization of the IgG response in the A/J model
revealed that no DEN-specific IgG Abs were found in sera
from mock-infected mice, whereas anti-DEN IgG Abs
were detected in d7 and d14 sera from DEN-infected mice,
with a higher titer in d14 sera. These data agree with
clinical findings, in which people develop a DEN-specific
IgG response later in the course of a primary infection
(Innis, 1997). Studies have shown that sera from infected
individuals or anti-DEN monoclonal IgG Abs neutralize
epitopes required for viral entry (Gentry et al., 1982;
Russell and Nisalak, 1967) and opsonize DEN for com-
plement-mediated lysis (Falgout et al., 1990) and Ab-
dependent, cell-mediated cytotoxicity (ADCC) (Kurane et
al., 1986). Several experiments have also supported a role
for serotype-cross-reactive IgG Abs in the pathogenesis of
DHF/DSS via the ‘‘Ab-dependent enhancement (ADE)’’
effect (Burke et al., 1988; Daughaday et al., 1981; Halstead
and O’Rourke, 1977; Halstead et al., 1980). As a follow-up
to these human studies, the A/J model could be used to
examine the protective versus the pathogenic nature of
both the IgM and IgG response to DEN infection. Initially,
adoptive transfer experiments using naive versus DEN-
immunized sera should determine whether pretreatment of
mice with DEN-specific IgM or IgG Abs protects mice
from DEN-induced disease.
IFNc production
A significant level of IFNg was detected in unstimulated
spleen cell cultures from DEN-infected A/J mice on d14 p.i,
but not from mock-infected mice, suggesting a role for IFNg
in primary DEN infection. IFNg may also play both a
protective and pathogenic role in DEN infection. The
protective nature of IFNg has been demonstrated by several
studies: (i) IFNg inhibits DEN infection in both transformed
and non-transformed human cells (Diamond and Harris,
2001; Diamond et al., 2000b), and (ii) mice lacking recep-
tors for both IFNa/h and IFNg succumb to DEN infection,
whereas wild-type counterparts survive (Johnson and Roeh-
rig, 1999). The pathogenic nature of IFNg has been implied
by the findings that (i) some CD4+ cytotoxic T cell (CTL)
clones with serotype-cross-reactivity produce significant
levels of IFNg (Gagnon et al., 1999), (ii) patients with
DHF/DSS have higher levels of IFNg, as compared to
individuals with DF (Green et al., 1999b; Kurane et al.,
1991b), and (iii) IFNg enhances Fcg receptor-mediated
DEN infection of U937 cells, a human monocytic cell line
(Kontny et al., 1988). Further studies using mice lacking
IFNg should help determine the precise role of this cytokine
in DEN infection in vivo and are currently underway.
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of splenic NK cells was observed, suggests that IFNg
production may not be a major effector mechanism of these
activated NK cells and that direct antiviral activities of IFNg
at early times post-infection may be less important. Based
on other viral infection models, IFNg may be playing an
immunomodulatory role, and T cells are the likely candi-
dates to produce IFNg at d14 p.i. (Hooper et al., 2002).
Indeed, CD4+T cells, but not CD8+T cells, produced IFNg at
d14 p.i., and this result supports the observation that a
higher frequency of CD44hiCD4+T cells, which represent
activated or memory CD4+T cells, was found in the d14
spleens of DEN-infected mice than in the spleens of mock-
infected mice (data not shown). Importantly, several human
studies have suggested a role for CD4+T cells in DEN
infection. For example, PBMCs isolated from infected
patients contain DEN-specific CD4+T cells that mediate
cytotoxicity in vitro and secrete IFNg after stimulation with
DEN antigen (Bukowski et al., 1989; Kurane et al., 1991a).
Again, further studies using wild-type and IFNg-deficient
mice should help determine the mechanisms by which
CD4+T cells regulate the immune response to DEN infection
in vivo through IFNg production.
In summary, this study has extended the characterization
of a more suitable mouse model for DEN infection. The new
virologic, hematologic, and immunologic data, in combina-
tion, now set the stage for investigating both the host- and
virus-specific mechanisms that control primary and sequen-
tial DEN infections. Understanding the cellular and molec-
ular basis of DEN infection and disease should contribute to
the development of effective therapeutics and vaccines as
well as a better small animal model for vaccine testing.Methods
Mice
Sex-matched, 4- to 5-week-old A/J mice were purchased
from the Jackson Laboratory (Bar Harbor, ME) and were
housed under specific pathogen-free conditions in the bio-
safety level 2 (BSL2) animal facility at the University of
California (UC), Berkeley. After 1 week of rest in the
facility, 5- to 6-week-old mice were used for experiments.
All experiments were approved and conducted as per the
guidelines of the Office of Laboratory Animal Care at UC
Berkeley.
DEN2 infection of mice
DEN2 strain PL046, a Taiwanese isolate, was originally
obtained from Dr. Huan-Yao Lei (National Cheng Kung
University, Taiwan). Viral stocks were grown in the A.
albopictus C6/36 cell line using ‘‘complete L15,’’ which
contained endotoxin-free L15 medium supplemented with
5% heat-inactivated fetal calf serum (FCS; Omega Scientif-ic, Tarzana, CA) for 5–7 days at 28 jC. Culture super-
natants containing virus were harvested, frozen, and stored
at 80jC, as previously described (Diamond et al., 2000a,
2000b). Viral titer was determined by a standard plaque
assay using BHK-21 cells (Diamond et al., 2000a, 2000b).
Virus stocks from the same passage (P = 2) were used to
infect all animals in this study. For injection into mice,
frozen stocks containing 5  106 to 5  107 plaque forming
units (PFU)/ml were thawed, concentrated by ultracentrifu-
gation (43000  g for 2.5 h), and resuspended in endotoxin-
free, ice-cold phosphate-buffered saline (PBS). An inocu-
lum containing 108 PFU in 100–200 Al was injected into the
tail vein of each experimental mouse, and the same volume
of PBS or 108 PFU of heat-inactivated DEN (incubated at
100 jC for 5 min) was injected intravenously into each
mock control mouse. In all experiments, no difference was
observed between PBS- and heat-inactivated DEN-injected
mice; thus, results from these two groups were pooled and
designated as the mock values. The exact numbers of mice
per group are indicated in the figure legends. Since 100% of
mice inoculated with 107 PFU of DEN survived, and no
significant difference was found in mice infected with 108
PFU versus 2  108 PFU, results from experiments using
only 108 PFU are shown in all figures.
Quantitation of virus in infected mice
To assess viral burden in tissues of infected mice, organs
were harvested, weighed, and homogenized using zirconia/
silica beads (1.0 mm diameter) with a Mini-Beadbeater-
8 apparatus (BioSpec Products, Bartlesville, OK), and
microcentrifuged (10 min, 4 jC, 14000 rpm) to pellet
debris. Serum was isolated from whole blood that was
obtained via a cardiac puncture of mice immediately after
euthanasia by isofluorane inhalation. The following three
different assays were performed to measure the amount of
infectious virus or viral RNA in supernatants of tissue
homogenate and serum samples:
(i) Direct plaque assay: Infectious virus in 1:10 serial
dilutions of organ homogenates was titered using a
standard plaque assay on BHK-21 cells, as above.
(ii) Indirect plaque assay: Supernatants of tissue homoge-
nates (75 or 7.5 Al/well for liver) and sera (7.5 Al/well)
were incubated with C6/36 cells in a 24-well plate (3 
105 cells/0.25 ml complete L15 medium/well) at 28 jC.
Following an overnight incubation, an additional 0.5
ml/well of complete L15 medium was added. After 6–7
days, culture supernatant was harvested and titered in
plaque assays using BHK-21 as described above.
(iii) Real-time RT-PCR: For analysis of total viral RNA in
tissues, samples were submerged into RNAlater (Qia-
gen, Valencia, CA) immediately after dissection and
kept at 4 jC overnight, followed by long-term storage at
80jC. Frozen samples were thawed and homogenized
using the Mini-Beadbeater-8 just before the isolation of
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minikit (Qiagen). Viral RNA from thawed aliquots of
serum (10–15 Al) was isolated using a Qia-Amp viral
RNA recovery kit (Qiagen). RNA samples, eluted in
RNAse-free water, were snap-frozen in liquid nitrogen
for storage. Quantitative measurements of total viral
RNA were obtained using Taqman reagents (One Step
RT-PCR Kit; Applied Biosystems, Foster City, CA) and
an ABI PRISM 7700 sequence detection system
(Applied Biosystems) according to a published protocol
(Houng et al., 2000). To control for RNA content and
quality, the level of glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH) mRNA in each sample was
measured using a Taqman rodent GAPDH control kit
(Applied Biosystems) in parallel real-time RT-PCR
reactions. A four-point standard curve was run on each
plate for determining the DEN and GAPDH RNA
levels. To generate the DEN standard curve, viral RNA
was isolated from a sample containing a known number
of PFU, and real-time RT-PCR reactions were per-
formed with serial dilutions of this RNA. The GAPDH
standard curve was based on known amounts of total
mouse RNA that was provided by the manufacturer
(Applied Biosystems). Samples were run in duplicate,
and viral RNA was quantitated as the PFU of DEN
RNA per milligram of total mouse RNA. Each PFU of
DEN contains approximately 1  103 to 5  103 copies
of viral RNA, as measured by real-time PCR in
comparison with known numbers of viral RNA
molecules (Edgil et al., in press).
Preparation of spleen cell suspension
Spleens were harvested and placed in complete RPMI
medium consisting of RPMI 1640 medium (Invitrogen,
Carlsbad, CA) supplemented with 10% heat-inactivated
FCS (Omega Scientific), 10 mM HEPES, 200 mM L-
glutamine, 10000 U/ml penicillin and streptomycin, 50
mM 2-mercaptoethanol, and 1% nonessential amino acids.
Single-cell suspensions were made by mechanically disrupt-
ing the tissue between the frosted ends of two glass slides.
Red blood cells were lysed using a buffered ammonium
chloride (ACK) solution, and cell suspensions were washed
and resuspended in complete RPMI 1640. Aliquots of cell
suspensions were stained with trypan blue, and viable cells
were counted using a hemocytometer. To test for the
spontaneous secretion of cytokines, splenocytes were incu-
bated in 96-well round-bottom plates (106 cells/well, in
triplicate) for 24 h in complete RPMI 1640 (200 Al/well),
followed by centrifugation (450  g for 5 min) to pellet
cells; then the supernatant was harvested and stored at 20
jC. To identify the cell types that produced IFNg, CD4+,
and CD8+ T cell subsets in the spleen cell suspension were
depleted via a standard complement-mediated lysis proto-
col. Briefly, splenocytes were incubated with anti-mouse
CD4 (clone RL172) and anti-mouse CD8 (clone 3.155)hybridoma supernatants (107 cells/ml, 1 h, 4 jC), washed,
and resuspended in complete RPMI 1640 (107 cells/ml).
Cells were incubated with rabbit and guinea pig comple-
ment (1/16 of total cell volume, 1 h, 37 jC), washed, and
allowed to settle. Cell debris was removed, viable cells were
counted via trypan blue exclusion, and cells were then
plated in 96-well round-bottom plates, as described above.
Cytokine ELISAs
To determine IFNg and TNFa levels in spleen culture
supernatants and sera, standard sandwich ELISAs were
performed. To detect mouse IFNg, anti-mouse IFNg clone
R4-6A2 (Caltag Laboratories, Burlingame, CA) and bio-
tinylated anti-mouse IFNg clone XMG1.2 (Caltag Labora-
tories) were used as capture and detection Abs, respectively.
To assay for mouse TNFa, anti-mouse TNFa clone
1F3F3D4 (eBioscience, San Diego, CA) was used as the
capture Ab, in combination with biotinylated anti-mouse
TNFa cocktail (clones MP6-XT3 and MP6-XT22; eBio-
science) as the detection Abs. All procedures were per-
formed according to manufacturers’ protocols, and the limits
of detection were 15 and 100 pg/ml for IFNg and TNFa,
respectively. Colorimetric changes of tetramethyl benzidine
(TMB) enzyme substrate (Sigma Co., St. Louis, MO) were
detected using a Bio-Tek Elx808 microplate reader (Bio-Tek
Instruments, Winooski, VT) and KCjunior software (Bio-
Tek Instruments).
Flow cytometry
Spleen cell suspensions were aliquoted (1–2  106 cells/
sample) and centrifuged at 220  g, and the cell pellets were
resuspended in 100 Al of supernatant from anti-mouse CD16
hybridoma (clone 24G2) to block Fc receptors (30 min, 4
jC). Cells were then washed once in FACS buffer (PBS/
2.5% FCS/0.05% NaN3), followed by resuspension in FACS
buffer containing fluoroscein-labeled anti-mouse CD69 or
CD11c (0.1 Ag/106 cells; Pharmingen, San Diego, CA),
Phycoerythrin (PE)-labeled anti-NK1.1 (0.1 Ag/106 cells;
Pharmingen), PE-Cy5-labeled anti-mouse CD3 (0.1 Ag/106
cells; eBioscience), and TRI-COLOR-labeled anti-mouse
CD4, CD8, CD19, F4/80, or Gr1 (0.05 Ag/106 cells; Caltag
Laboratories). Samples were incubated on ice for 30 min in
the dark, washed twice with 200 Al of FACS buffer, resus-
pended in 200 Al of 1% paraformaldehyde, and stored at 4
jC until they were analyzed using a Coulter EPICS XL-
MCL (Beckman Coulter, Miami, FL) flow cytometer. Data
were acquired and saved in the list mode and then reanalyzed
using FlowJo software (Tree Star, San Carlos, CA).
ELISA for virus-specific antibody
C6/36 cells infected with DEN2 (PL046 strain) for 5
days and uninfected C6/36 cells were washed in PBS three
times, freeze-thawed five times using dry ice/ethanol and
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Maxisorp immunoplates (Nalge Nunc International, Ros-
kilde, Denmark). Each 96-well plate was coated with both
DEN-infected C6/36 (48 wells) and uninfected C6/36 (48
wells) lysates. The plates were washed twice with PBS/
0.05% Tween-20, blocked with PBS/10% FCS/0.05% NaN3
(2 h; RT), and washed three times in PBS/0.05% Tween-20.
Twofold serum dilutions starting at 1:100 were added to the
plates and incubated (3 h; RT), followed by five washes
with PBS/0.05% Tween-20. Bound Ab was detected with
IgM- or IgG-specific horseradish peroxidase-labeled goat
anti-mouse antibodies (0.5 Ag/ml; Southern Biotechnology
Associates, Birmingham, AL), using TMB as the substrate
(Sigma Co.). After stopping the reactions with 2 M H2SO4,
the OD was measured at 450 nm in a Bio-Tek Elx808
microplate reader (Biotek Instruments). The OD value for
uninfected C6/36 cellular antigen was first subtracted from
that of the corresponding wells coated with DEN2-infected
C6/36 lysates to obtain the adjusted OD value, and then Ab
titers were determined as the greatest serum dilution with an
absorption of twice the background levels.
Hematocrit and WBC count
Immediately after a cardiac puncture, blood was collect-
ed using a 1-ml plastic transfer pipette and placed into an
EDTA-coated Microtainer tube (Becton Dickinson Vacu-
tainer Systems, Franklin Lakes, NJ). The anticoagulated
blood sample was thoroughly mixed and processed using
the Unopette microcollection system (Becton Dickinson
Vacutainer Systems) for a manual WBC count on a
hemocytometer. Thin blood smears were checked to verify
the absence of clots, and clotted samples were discarded.
The remaining blood sample was drawn into a micro-
hematocrit capillary tube (Fisher Scientific, Pittsburgh,
PA), which was then plugged at one end with Cha-seal
(Fisher Scientific) and spun in a micro-hematocrit centri-
fuge for 5 min. After spinning, the percentage of total
volume occupied by the packed red blood cells was read on
a micro-hematocrit capillary tube reader (Sherwood Med-
ical, St. Louis, MO).
Statistical analyses
Statistical analyses were performed in Microsoft Excel X
(Microsoft Corporation, Seattle, WA), and values are shown
as mean F standard deviation (SD). To plot the outcome of
infected mice, Kaplan–Meier analysis was performed using
GraphPad Prism software, version 3.0cx (GraphPad Soft-
ware, Inc., San Diego, CA).Acknowledgments
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